Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory…
A new antibody therapy achieves strong, durable responses in a rare aggressive lymphoma where few options previously existed, offering hope for patients with limited treatment choices.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Researchers identified how lung cancers resist targeted therapy and showed in models that combining existing drugs overcomes this resistance, supporting upcoming clinical trials.
Standard additionPrognostic Impact of Sequential Measurable Residual Disease and KIT…
Checking blood cancer levels multiple times during treatment—not just once—better predicts which children will relapse, allowing doctors to tailor intensity and potentially improve outcomes.
Near-term implementable findingMultimodal Artificial Intelligence System for Risk-Adapted Cancer…
AI can identify which treated nasopharyngeal cancer patients truly need intensive monitoring versus those unlikely to relapse, cutting unnecessary clinic visits by over 90% for low-risk survivors.
Novel or significantly improved treatmentHematopoietic cell transplantation for blastic plasmacytoid dendritic…
The first expert guidelines for transplanting patients with a rare aggressive blood cancer provide clarity where doctors previously had to navigate treatment decisions alone.